QNRX
Quoin Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · US
$7.26
−7.75%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$14.58M
MomentumView details →
1D Return
−7.75%
YTD Return
−49.97%
RSI (14)
67.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$14.58M
RSI (14)
67.4
MomentumView details →
1D Return
−7.75%
YTD Return
−49.97%
SummaryUpdated Jun 1, 2026
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) is a specialty pharmaceutical company founded in 2016 and based in Ashburn, Virginia. The company focuses exclusively on developing therapeutic products for rare and orphan diseases, particularly rare skin conditions that affect small patient populations with significant unmet medical needs. Since its initial public offering in August 2016, Quoin has concentrated its efforts on advancing a pipeline of topical treatments through clinical development, with its lead candidate targeting Netherton Syndrome, an extremely rare genetic skin disorder.
Similar companies
Latest newsMore news →
Quoin Pharmaceuticals announced positive clinical trial results for its product on Friday morning.7d agoQuoin Pharmaceuticals entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds through a private placement of ordinary shares and warrants.8d agoQuoin Pharmaceuticals received FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome, received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, and submitted an IND for Peeling Skin Syndrome with FDA clearance received after quarter end.21d ago